Mira Pharmaceuticals reports positive 7-day rat, dog tox studies for oral pain drug MIRA-55 ahead of IND push

• Mira Pharmaceuticals reported positive early-stage animal safety results for oral, non-opioid inflammatory pain candidate MIRA-55.
• Results have already been presented, positioning the program to select doses for the next IND-enabling toxicology studies.
• Studies indicated tolerability across species, supporting continued development toward first-in-human testing.
• IND submission is targeted for Q1 2027, pending completion of remaining preclinical requirements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-040930), on September 01, 2026, and is solely responsible for the information contained therein.